Citigroup Begins Coverage on Henry Schein (NASDAQ:HSIC)

Stock analysts at Citigroup initiated coverage on shares of Henry Schein (NASDAQ:HSIC) in a note issued to investors on Wednesday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $100.00 price target on the stock. Citigroup’s price target would suggest a potential upside of 26.33% from the company’s previous close.

Other equities research analysts have also recently issued reports about the stock. Leerink Partners reissued a “market perform” rating on shares of Henry Schein in a research note on Monday, March 9th. Robert W. Baird set a $100.00 target price on shares of Henry Schein and gave the stock an “outperform” rating in a research report on Monday, February 23rd. Wells Fargo & Company increased their price target on shares of Henry Schein from $76.00 to $87.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 25th. Wall Street Zen cut shares of Henry Schein from a “strong-buy” rating to a “buy” rating in a research note on Saturday, March 14th. Finally, UBS Group lifted their price objective on Henry Schein from $79.00 to $87.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 25th. Seven research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $86.69.

Henry Schein Stock Up 2.5%

Shares of HSIC traded up $1.95 during mid-day trading on Wednesday, reaching $79.16. The company’s stock had a trading volume of 58,651 shares, compared to its average volume of 1,291,165. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.38 and a quick ratio of 0.76. Henry Schein has a 12-month low of $61.94 and a 12-month high of $89.29. The company’s 50 day moving average is $76.93 and its 200 day moving average is $73.87. The stock has a market cap of $9.08 billion, a PE ratio of 24.21, a price-to-earnings-growth ratio of 2.29 and a beta of 0.88.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.30 by $0.04. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.The firm had revenue of $3.44 billion during the quarter, compared to analysts’ expectations of $3.34 billion. During the same period in the prior year, the firm earned $1.19 EPS. The business’s revenue was up 7.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Equities analysts anticipate that Henry Schein will post 4.74 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Thomas C. Popeck sold 1,355 shares of the firm’s stock in a transaction that occurred on Thursday, March 19th. The shares were sold at an average price of $72.79, for a total transaction of $98,630.45. Following the completion of the sale, the chief executive officer owned 86,182 shares of the company’s stock, valued at approximately $6,273,187.78. This trade represents a 1.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Philip A. Laskawy sold 2,844 shares of the company’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $80.36, for a total transaction of $228,543.84. Following the completion of the sale, the director owned 21,961 shares in the company, valued at approximately $1,764,785.96. This trade represents a 11.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 105,911 shares of company stock worth $8,574,982 over the last 90 days. 1.08% of the stock is currently owned by corporate insiders.

Institutional Trading of Henry Schein

Several hedge funds have recently bought and sold shares of HSIC. AQR Capital Management LLC increased its stake in Henry Schein by 47.3% during the 1st quarter. AQR Capital Management LLC now owns 30,402 shares of the company’s stock valued at $2,071,000 after buying an additional 9,756 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Henry Schein by 1.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,859 shares of the company’s stock valued at $1,155,000 after buying an additional 229 shares in the last quarter. Acadian Asset Management LLC purchased a new position in Henry Schein during the 1st quarter worth approximately $676,000. Cetera Investment Advisers raised its position in Henry Schein by 12.9% during the second quarter. Cetera Investment Advisers now owns 5,561 shares of the company’s stock valued at $406,000 after buying an additional 637 shares during the period. Finally, First Trust Advisors LP lifted its position in shares of Henry Schein by 0.8% in the second quarter. First Trust Advisors LP now owns 221,130 shares of the company’s stock worth $16,154,000 after purchasing an additional 1,669 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.